Fresenius expects to launch Humira biosimilar in 2019German healthcare group Fresenius expects to launch its biosimilar of AbbVie's Humira (adalimumab) Idacio this year, FAZ (p19), Sueddeutsche Zeitung (SZ) (p13), Handelsblatt (p19) and Die Welt (p12) reported on Thursday (APMHE 61963).
German payer testing e-prescriptionsGerman major payer TK is about to start testing e-prescriptions in the Hamburg city district of Wandsbek, Die Welt reported on Tuesday (p13).
J&J's depression spray backed by FDAJohnson & Johnson's experimental nasal spray Spravato (esketamine) for treatment-resistant depression was backed by 14 of 17 advisers to the U.S. Food and Drug Administration, Die Welt reported on Sunday (p20) (APMHE 61843).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.